Stockscreener 앱 받기
7.43
3.13%
-0.24
시간 외 거래:
7.43
전일 마감가:
$7.67
열려 있는:
$7.27
하루 거래량:
1.89M
Relative Volume:
1.16
시가총액:
$1.12B
수익:
$177.28M
순이익/손실:
$-195.24M
주가수익비율:
-5.5448
EPS:
-1.34
순현금흐름:
$-114.54M
1주 성능:
-14.20%
1개월 성능:
-10.05%
6개월 성능:
+45.12%
1년 성능:
+131.46%
1일 변동 폭
$7.1126
$7.68
1주일 범위
$7.1126
$8.74
52주 변동 폭
$2.28
$9.01
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.43 | 1.12B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Underperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 재확인 | BTIG Research | Buy |
| 2022-02-16 | 재확인 | BofA Securities | Buy |
| 2022-02-16 | 재확인 | Goldman | Neutral |
| 2022-02-16 | 재확인 | JP Morgan | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 개시 | Goldman | Buy |
| 2019-07-23 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | BofA/Merrill | Buy |
| 2019-07-22 | 개시 | Cowen | Outperform |
| 2019-07-22 | 개시 | Goldman | Neutral |
| 2019-07-22 | 개시 | Guggenheim | Buy |
| 2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Swiss National Bank Takes $1.22 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Proficio Capital Partners LLC Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp: Analyzing ADPT Stock Trends - investchronicle.com
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 - Investing.com India
Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies stock hits 52-week high at $8.95 By Investing.com - Investing.com Australia
Adaptive Biotechnologies stock hits 52-week high at $8.95 - Investing.com
Amundi Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next? - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
Bank of New York Mellon Corp Has $2.18 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close - MarketScreener
Analyst Expectations For Adaptive Biotechnologies's Future - Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Benzinga
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8 - Marketscreener.com
Goldman Sachs Upgrades Adaptive Biotechnologies (ADPT) - MSN
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March - Insider Monkey
10 Stocks Insiders Are Selling In March - Insider Monkey
Proficio Capital Partners LLC Takes $93,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.1% on Insider Selling - Defense World
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com India
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies Executives Sell Shares - TradingView
Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CFO sells shares worth $72,072 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies chief people officer sells $145,845 in stock - Investing.com
Adaptive Biotechnologies chief people officer sells $145,845 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies director sells $124,372 in stock - Investing.com India
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock - Investing.com
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock - Investing.com
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock - Investing.com
Private Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Increased by Rhumbline Advisers - Defense World
D.A. Davidson & CO. Buys 6,725 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies’ (ADPT) “Overweight” Rating Reiterated at Piper Sandler - Defense World
Cathie Wood’s Ark Invest Makes Bold Moves: Buys BEAM & NU, Sells MELI & ADPT - Apna Kal
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive BiotechnologiesARK Fintech Innovation ETF (ARCA:ARKF), Adaptive Biotechnologies (NASDAQ:ADPT) - Benzinga
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):